.... Small- and intermediate-conductance Ca 2+ -activated potassium channels Small-molecule positive modulators Structure-based drug discovery Ataxia Alcohol use disorders Parkinson’s disease The small- and intermediate-conductance Ca 2+ -activated potassium (SK/IK) channels belong...

... stimulation (DBS) could in the near future optimize stimulation settings online so as to achieve better control over the clinical fluctuations in Parkinson's disease (PD). Local field potentials (LFPs) recorded from the subthalamic nucleus (STN) in PD patients show that levodopa and DBS modulate STN...

... -aspartate receptors, by antisense oligos amelio-rated the motor symptoms in the 6-hydroxydopamine (6-OHDA)-lesioned rat, an animal model of Parkinson's disease (PD) [Lai et al.: Neurochem Int 2004;45:11-22]. To further the investigation on the efficacy of gene silencing, small interference RNA (siRNA...

... of neurotensin in globus pallidus of parkinsonian rats, we hypothesize that the pallidal neurotensinergic system may be involved in its possible therapy in Parkinson’s disease. 22 01 2008 23 07 2008 7 2 2009 © 2009 S. Karger AG, Basel 2009 Copyright / Drug Dosage / Disclaimer Copyright...

...Benoit I. Giasson; Vivianna M. Van Deerlin Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of late-onset Parkinson’s disease (PD). Clinical and pathological studies have demonstrated that in the majority of cases LRRK2 mutations lead to PD with classical clinical...

.... Neurology 1988; 38:1237 1244. 3 Double KL, Rowe DB, Hayes M, Chan DK, Blackie J, Corbett A, Joffe R, Fung VS, Morris J, Halliday GM: Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 2003;60:545 549. 4 Hawkes CH, Shephard BC, Daniel SE...

... highlight recent work investigating mechanisms of cellular toxicity in a yeast Parkinson’s disease model and discuss how similar approaches are being applied to additional neurodegenerative diseases. 5 12 2007 © 2008 S. Karger AG, Basel 2007 Copyright / Drug Dosage / Disclaimer Copyright...

...Rachel Goldmann Gross; Andrew Siderowf; Howard I. Hurtig Parkinson’s disease (PD) is classically thought of as a movement disorder characterized by tremor, rigidity and postural instability. Nevertheless, there is growing recognition of prominent cognitive impairment in PD and related disorders...

... of Neurosignals focus on research at PENN that is designed to prevent or ameliorate aging-related neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis and frontotemporal dementia. This research could enhance our chances of aging successfully in the continuing...

.... It is believed that temporal information carried along the corticostriatopallidal pathway is critical for proper motor execution. The importance of appropriately controlled discharge of GP neurons is highlighted by psychomotor disorders such as Parkinson’s disease, in which alterations in the pattern...

...Peter J. Houghton; Melanie-Jayne Howes The two major neurodegenerative diseases Alzheimer’s disease (AD) and Parkinson’s disease (PD) are characterised by low levels in the brain of the neurotransmitters acetylcholine (ACh) and dopamine (DA), respectively. Clinical treatment of these two conditions...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. (–)-Epigallocatechin-3-gallate Neurorescue Neurodegeneration Neuroprotection Parkinson’s disease Neurite outgrowth Green tea catechins Iron chelation Cell signaling...

..., serious disturbances occur. Many neurodegenerative diseases including Parkinson’s disease involve aggregation and deposition of misfolded proteins such as α-synuclein. Endogenously occurring neurotoxins such as Salsolinol and 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ) causing Parkinsonism may foster...

...M. Ebadi; P. Govitrapong; S. Sharma; D. Muralikrishnan; S. Shavali; L. Pellett; R. Schafer; C. Albano; Josh Eken Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease affecting approximately1% of the population older than 50 years. There is a worldwide...